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antipsychotic-stimulant group. No statistically significant difference was found in 
the risk of cardiovascular events among patients with mood stabilizer-stimulant 
combination (HR= 0.98, 95% Confidence Interval, 95% CI: 0.49-1.99) or antipsy-
chotic-stimulant combination (HR= 0.57, 95% CI: 0.31-1.05) compared to stimulant 
monotherapy. ConClusions: The current study did not find any difference in the 
cardiovascular risk after addition of mood stabilizer or atypical antipsychotic to 
stimulant monotherapy in patients with ADHD and bipolar disorder. More studies 
are needed to evaluate overall safety profiles of these therapeutic combinations in 
patients with comorbid ADHD and bipolar disorder.
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objeCtives: Clinical trials showed insignificant effects of statins on preventing car-
diovascular diseases(CVD) among hemodialysis patients. This study is to examine the 
association between discontinuation of statin use after hemodialysis and the risk of 
CVD. Methods: We conducted a population-based retrospective cohort study using 
year 1997-2008 National Health Insurance Research Database. We selected patients 
who are 20 years old or above and first time receiving maintenance hemodialysis. 
The selected patients were also those prescribed statins at least once in the 180 
days before the first hemodialysis. We excluded the patients who had medical his-
tory of kidney transplantation or maintenance peritoneal dialysis. Continuous use 
of statins was defined as receiving prescriptions of statins in the first 90 days after 
hemodialysis. We used the Cox proportional hazards model to analyze the associa-
tion between the discontinuation status and the risk of hospitalization or surgeries 
for coronary heart diseases (CHD) and non-hemorrhagic stroke. The propensity score 
method was used to adjust the self-selection bias in the statin user and non-user 
groups. Results: Among 8,949 patients examined, 2,079 (23.2%) patients used statins 
in the first 90 days after hemodialysis. After adjusted by the propensity score, the Cox 
model showed discontinuation of statin use in the first 90 days after dialysis was not 
associated with higher risk of hospitalization or surgeries for CHD and non-hem-
orrhagic stroke (HR 0.55ï¿½, 95% CI 0.50, 0.61) compared to statin users. The results 
were consistent when stratifying the patients into those with medical history of CVD 
(n= 5288, HR 0.53ï¿½, 95% CI 0.47, 0.60) and those without (n= 3661, HR 0.61, 95% CI 
0.50, 0.74). ConClusions: Discontinuation of statin use after hemodialysis does not 
increase the risk of hospitalization or surgeries for CHD and non-hemorrhagic stroke. 
However, this result cannot rule out the possible association between the severity of 
hypercholesterolemia or predicted risk of CVD and statin use.
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objeCtives: A novel genotype-guided personalized warfarin dosing (PGx) service 
was implemented at the University of Illinois Hospital & Health Sciences System. 
The aim of this study was to examine the impact of race on the association between 
the (PGx) service and anticoagulation related clinical outcomes. Methods: 
Multivariate linear, logistic, and survival models were used to examine differences 
across race in the association between the PGx service and several clinical outcomes. 
These models were adjusted for confounders, and inverse probability treatment 
weight propensity scoring was used. Our primary outcome of interest was time to 
first therapeutic INR. Results: A total of 339 patients managed by the PGx service 
(mean age 56±16 years; 61% African-American; 55% female) and 299 historical con-
trols (mean age 54±16 years; 74% African-American, 64% female) were included. 
In our primary outcome, the treatment effect in time to first therapeutic INR was 
significantly higher in African-Americans compared to Caucasians (HR: 1.86, 95%CI: 
1.3, 2.8 vs. HR: 1.24, 95%CI: 0.4, 3.8, respectively). The treatment effect in time in 
therapeutic international normalized ratio (INR) range was significantly higher in 
African-Americans than in Caucasians over the initial 7 days of therapy (β : 5.52 
days, 95% CI: 1.4, 9.6 vs. β : 0.78, 95%CI: -9.3, 10.8, respectively). The treatment effect 
in proportion of INRs at extremes (< 1.5 and > 4) was lower in African-Americans 
compared to Caucasians (β : -25.56, 95% CI: -31.6, -19.6 vs. β : -22.46, 95% CI: -36.8, 
-8.2, respectively). Additionally, relative to Caucasians, African-Americans in the PGx 
group were 2.17 times more likely to have an INR in therapeutic range at discharge 
(OR: 2.17, 95% CI: 1.0, 4.7). ConClusions: A novel genotype-guided personalized 
warfarin service was positively associated with anticoagulation related clinical out-
comes, and this association was stronger in African-American patients.
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objeCtives: eHealth is the transfer of health resources, care, and data by electronic 
means and has the potential to promote reductions in the cost of care. It has been 
employed by medical professionals to manage chronic diseases outside of a clinical 
setting, provide useful data for decision making, and deliver timely information and 
care to the patient. This review assesses the use of eHealth programs in chronic 
disease management and identifies the settings and patient populations that have 
resulted in successful outcomes. Methods: A systematic literature review was 
conducted in Embase, Medline, CINAHL, and PsycINFO. Inclusion criteria were 
English language studies since 2005 evaluating the efficacy of an eHealth program 
on patients with chronic disease(s). Studies in which e-mail communication was 
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objeCtives: Venous thromboembolism (VTE) is one of the major complications 
after major orthopedic surgeries (MOS). In 2011, FDA approved rivaroxaban for VTE 
prevention among patients undergoing MOS. The aim of our study is to empirically 
evaluate the comparative effectiveness of rivaroxaban, warfarin, and low molecu-
lar weight heparins (LMWHs) for VTE prevention among MOS patients using “real 
world” data. Methods: A cohort study using IMS Lifelink Plus (2006-2013) data 
compared the risk of VTE and major bleed events among MOS patients exposed 
to rivaroxaban, warfarin, LMWHs, or fondaparinux with those who are not anti-
coagulated within 7 days after their MOS-hospital discharge. Kaplan Meier curves 
and Cox proportional hazard models were used to assess the risk of VTE and major 
bleed events and to adjust for potential confounders. Results: A cohort of 35,279 
MOS were included which provided 68,340 person years of follow up including 1,004 
rivaroxaban, 7,339 warfarin, 5,692 LMWH, 841 fondaparinux exposed patients and 
20,403 patients who did not receive an initial anticoagulant. Risk of VTE was low-
est for rivaroxaban (H.R.= 0.282; 95%CI:0.156-0.510) followed LMWHs (H.R.= 0.671 
[95%CI= 0.582-0.773]), fondaparinux (H.R.= 0.680 [95%CI = 0.485-0.951]) and warfa-
rin (H.R.= 0.872 [95%CI= 0.778-0.978]) when compared to no anticoagulant use in 
unadjusted cox models. After adjusting for potential confounders, only rivaroxaban 
(H.R.= 0.395 [95%CI= 0.215-0.742]) and LMWHs (H.R.= 0.755[95%CI= 0.643-0.873]) sig-
nificantly reduced the risk of VTE. However, these results were not significant in 
a sensitivity analysis using a more strict definition to detect VTEs in claims data. 
There were no bleed events for rivaroxaban users and the risk of bleed events were 
not significantly different among anticoagulants and non-anticoagulant exposure 
in both the adjusted and the unadjusted models. ConClusions: LMWHs and 
Rivaroxaban were associated with reduced VTE events and no detectable increase 
in major bleeds among MOS patients. These findings, particularly those on major 
bleed events, should be confirmed in larger study populations.
PCV9
estimatinG tHe lifetime CliniCal risk/Benefits of aPixaBan Versus 
eDoxaBan in non-ValVular atrial fiBrillation
Phatak H.1, Dorian P.2, Kongnakorn T.3, Lanitis T.4, Liu X.5, Mardekian J.6, Lawrence J.7, Lip G.8
1Bristol-Myers Squibb Company, Princeton, NJ, USA, 2University of Torono, Toronto, ON, Canada, 
3Evidera, Bangkok, Thailand, 4Evidera, London, UK, 5Pfizer, New York, NY, USA, 6Pfizer Inc., New 
York, NY, USA, 7BMS, Princeton, NJ, USA, 8University of Birmingham, Birmingham, UK
objeCtives: This analysis aimed to assess the potential clinical risk/benefits associ-
ated with the lifetime use of apixaban versus edoxaban in patients with non-valvular 
atrial fibrillation (NVAF) in the United States (US). Methods: A Markov model was 
developed to extrapolate the observed clinical impact of apixaban versus a regimen 
of edoxaban starting at 60 mg at the lifetime horizon. Outcomes assessed included 
the number of clinical events avoided for every 1000 patients treated, number of 
patients needed to treat to prevent one stroke, and number of patients needed to 
harm with an additional major bleed. Key sources of inputs used to populate the 
model included: indirect comparison data versus edoxaban from published blinded 
randomized trials vs warfarin; US life tables for life expectancy; published literature 
for increased mortality related to outcome events modeled. Results: In a cohort of 
1,000 patients, treatment with apixaban (at doses used in clinical trials) in comparison 
with edoxaban 60 mg resulted in 6 fewer strokes and caused 10 fewer major bleeds 
over the average projected lifetime. This translated in 172 patients needed to treat 
with apixaban versus edoxaban 60 mg to prevent one stroke with no additional major 
bleeding. The reduction in clinical events resulted in 29 additional discounted life-
years for the cohort of 1,000 patients treated with apixaban. ConClusions: Using an 
indirect comparison, lifetime use of apixaban is projected to increase life-expectancy 
versus edoxaban 60 mg QD in the US. It also appears to provide dual risk reduction 
based on efficacy and safety benefits versus edoxaban 60 mg starting regimen.
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objeCtives: This study compared the cardiovascular safety of the addition of mood 
stabilizers or atypical antipsychotics to stimulant monotherapy in children and ado-
lescents diagnosed with ADHD and bipolar disorder. Methods: This retrospective 
cohort study used 2004-2007 IMS LifeLink™ Health Plan Claims Database. Children 
and adolescents aged 6 to 17 years diagnosed with ADHD and bipolar disorder who 
initiated a new treatment with stimulants were followed for 12 months to compare 
the safety of addition of mood stabilizers or atypical antipsychotics to stimulant 
monotherapy. Only patients who had continuous eligibility 6 months before and 12 
months after the index stimulant date were selected. Exposure to a mood stabilizer 
or atypical antipsychotic agent after the initiation of the index stimulant treatment 
formed the primary exposure. The primary outcome was defined as the first hospi-
talization or emergency room (ER) visit for cardiovascular disorder identified using 
International Classification of Diseases- 9th Revision, Clinical Modification (ICD-9 
CM) codes. Cardiovascular risk was compared using time-varying Cox regression 
analysis adjusting for other cardiac risk factors. Results: Of the 1,769 ADHD and 
bipolar patients, 48.28% were prescribed stimulants only, 16.68% were on mood 
stabilizer-stimulant combination and 35.05% were on antipsychotic-stimulant 
combination therapy. The incidence of cardiovascular events were 5.15% in the 
stimulants-only group, 4.75% in the mood stabilizer-stimulant group and 8.87% in 
